SENOPAUSE: Evaluation of an ASCO-Derived Clinical Proxy for Axillary Risk Stratification in a Retrospective Cohort
In a real-world cohort meeting strict ASCO proxy criteria, approximately 1 in ten patients had occult pN1 disease, yet chemotherapy use remained uncommon and WBRT was near-universal. These findings suggest nodal status may have limited impact on downstream adjuvant treatment escalation in highly selected low-risk luminal breast cancers.
Authors
- Léa Pauly (ORCID: https://orcid.org/0000-0001-9626-7428)
- Leslie Elahi (ORCID: https://orcid.org/0000-0003-2633-1740)
- Eugénie Guillot (ORCID: https://orcid.org/0000-0002-9154-2168)
- Nicolas Pouget
- Louise Maumy
- Michel Gabriel CAZENAVE
- Katia MAHIOU
- Mathis Trotin
- Grégoire Miahlhe
- Claire Bonneau
- Louise Benoit
Institutions
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Institut Curie (FR)
Publication Details
- Journal
- Clinical Breast Cancer
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1016/j.clbc.2026.02.013
- Primary Topic
- Dermatologic Treatments and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00